Endpoints Capital was founded to address the funding challenges that biotechnology companies face by providing a financing solution that benefits biotechs at all stages. We understand the life sciences ecosystem and the challenges - including financing - that biotech companies face getting their treatment or device into the clinic. This has been further compounded by the difficulties in capital markets in recent times.
We are excited by the opportunity to help biotechs accelerate their discovery of new medicines, therapies and life changing treatments.
Company Details
- Employees
- 8
- Founded
- -
- Address
- 81-83 Campbell St, Surry Hills,new South Wales 2010,australia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://endpointscapital.com.au/
- HQ
- Surry Hills, New South Wales
Endpoints Capital Questions
Endpoints Capital's website is https://endpointscapital.com.au/
Endpoints Capital's LinkedIn profile is https://au.linkedin.com/company/endpoints-capital
Endpoints Capital has
8 employees.
View email and phone details for 8
employees at Endpoints Capital.
Endpoints Capital's industry is
Biotechnology Research
Endpoints Capital's top competitors are
Attentive Science,
Radium Capital,
M.h. Carnegie & Co.,
Allier Capital,
Allegra Ventures,
Central Pharmacy Logistics Australia,
Crescent Capital Partners,
Pemba Capital Partners,
Australian Students Asset Management,
Genesis Capital.
Endpoints Capital's categories are Biotechnology Research
Endpoints Capital's founding year is 2023
